Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs

Ambrx Biopharma, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system, named Renu Vaish, M.Sc., as Chief Regulatory Officer.

Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Pharma, as well as other biopharma companies. Most recently, she served as the Senior Vice President, Regulatory Affairs at SpringWorks Therapeutics.

Ms. Vaish has a Master of Science in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences and a Bachelor of Science in Cell and Molecular Biology, from Concordia University.